Literature DB >> 35111651

A narrative review of MRI acquisition for MR-guided-radiotherapy in prostate cancer.

Jing Yuan1, Darren M C Poon2, Gladys Lo3, Oi Lei Wong1, Kin Yin Cheung1, Siu Ki Yu1.   

Abstract

Magnetic resonance guided radiotherapy (MRgRT), enabled by the clinical introduction of the integrated MRI and linear accelerator (MR-LINAC), is a novel technique for prostate cancer (PCa) treatment, promising to further improve clinical outcome and reduce toxicity. The role of prostate MRI has been greatly expanded from the traditional PCa diagnosis to also PCa screening, treatment and surveillance. Diagnostic prostate MRI has been relatively familiar in the community, particularly with the development of Prostate Imaging - Reporting and Data System (PI-RADS). But, on the other hand, the use of MRI in the emerging clinical practice of PCa MRgRT, which is substantially different from that in PCa diagnosis, has been so far sparsely presented in the medical literature. This review attempts to give a comprehensive overview of MRI acquisition techniques currently used in the clinical workflows of PCa MRgRT, from treatment planning to online treatment guidance, in order to promote MRI practice and research for PCa MRgRT. In particular, the major differences in the MRI acquisition of PCa MRgRT from that of diagnostic prostate MRI are demonstrated and explained. Limitations in the current MRI acquisition for PCa MRgRT are analyzed. The future developments of MRI in the PCa MRgRT are also discussed. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Magnetic resonance-guided-radiotherapy (MRgRT); diffusion weighted imaging (DWI); integrated magnetic resonance imaging and linear accelerator (MR-LINAC); multi-parametric magnetic resonance imaging (mpMRI); prostate cancer (PCa)

Year:  2022        PMID: 35111651      PMCID: PMC8739116          DOI: 10.21037/qims-21-697

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  103 in total

1.  Contouring of prostate tumors on multiparametric MRI: Evaluation of clinical delineations in a multicenter radiotherapy trial.

Authors:  Marcel A van Schie; Cuong V Dinh; Petra J van Houdt; Floris J Pos; Stijn W T J P Heijmink; Linda G W Kerkmeijer; Alexis N T J Kotte; Raymond Oyen; Karin Haustermans; Uulke A van der Heide
Journal:  Radiother Oncol       Date:  2018-05-03       Impact factor: 6.280

Review 2.  MRI simulation for radiotherapy treatment planning.

Authors:  Slobodan Devic
Journal:  Med Phys       Date:  2012-11       Impact factor: 4.071

Review 3.  Survey on deep learning for radiotherapy.

Authors:  Philippe Meyer; Vincent Noblet; Christophe Mazzara; Alex Lallement
Journal:  Comput Biol Med       Date:  2018-05-17       Impact factor: 4.589

4.  Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.

Authors:  Ting Martin Ma; James M Lamb; Maria Casado; Xiaoyan Wang; T Vincent Basehart; Yingli Yang; Daniel Low; Ke Sheng; Nzhde Agazaryan; Nicholas G Nickols; Minsong Cao; Michael L Steinberg; Amar U Kishan
Journal:  BMC Cancer       Date:  2021-05-11       Impact factor: 4.430

5.  Impact of the use of an endorectal coil for 3 T prostate MRI on image quality and cancer detection rate.

Authors:  Josephin Gawlitza; Martin Reiss-Zimmermann; Gregor Thörmer; Alexander Schaudinn; Nicolas Linder; Nikita Garnov; Lars-Christian Horn; Do Hoang Minh; Roman Ganzer; Jens-Uwe Stolzenburg; Thomas Kahn; Michael Moche; Harald Busse
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

Review 6.  Epidemiology of Prostate Cancer.

Authors:  Prashanth Rawla
Journal:  World J Oncol       Date:  2019-04-20

7.  Adaptive radiotherapy: The Elekta Unity MR-linac concept.

Authors:  Dennis Winkel; Gijsbert H Bol; Petra S Kroon; Bram van Asselen; Sara S Hackett; Anita M Werensteijn-Honingh; Martijn P W Intven; Wietse S C Eppinga; Rob H N Tijssen; Linda G W Kerkmeijer; Hans C J de Boer; Stella Mook; Gert J Meijer; Jochem Hes; Mirjam Willemsen-Bosman; Eline N de Groot-van Breugel; Ina M Jürgenliemk-Schulz; Bas W Raaymakers
Journal:  Clin Transl Radiat Oncol       Date:  2019-04-02

Review 8.  MR-Guided Radiotherapy for Prostate Cancer.

Authors:  Boris R Tocco; Amar U Kishan; Ting Martin Ma; Linda G W Kerkmeijer; Alison C Tree
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

9.  Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.

Authors:  Francesco Cuccia; Rosario Mazzola; Luca Nicosia; Vanessa Figlia; Niccolò Giaj-Levra; Francesco Ricchetti; Michele Rigo; Claudio Vitale; Beatrice Mantoan; Antonio De Simone; Gianluisa Sicignano; Ruggero Ruggieri; Stefano Cavalleri; Filippo Alongi
Journal:  Radiat Oncol       Date:  2020-07-22       Impact factor: 3.481

10.  Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study.

Authors:  Shyama U Tetar; Anna M E Bruynzeel; Swie S Oei; Suresh Senan; Tamara Fraikin; Berend J Slotman; R Jeroen A van Moorselaar; Frank J Lagerwaard
Journal:  Eur Urol Oncol       Date:  2020-06-12
View more
  2 in total

1.  A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.

Authors:  Darren M C Poon; Jing Yuan; Bin Yang; Oi-Lei Wong; Sin-Ting Chiu; George Chiu; Kin-Yin Cheung; Siu-Ki Yu; Raymond W H Yung
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

2.  Segmentation of the prostate, its zones, anterior fibromuscular stroma, and urethra on the MRIs and multimodality image fusion using U-Net model.

Authors:  Seyed Masoud Rezaeijo; Shabnam Jafarpoor Nesheli; Mehdi Fatan Serj; Mohammad Javad Tahmasebi Birgani
Journal:  Quant Imaging Med Surg       Date:  2022-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.